Ascletis Pharma
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Building D 198 Qidi Rd 12TH Fl, Hipark, ...Phone Number
+86 57185389730Website
www.ascletis.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Ascletis Pharma
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including small molecules and peptides for chronic weight management. Ascletis aims to address global unmet medical needs and is listed on the Hong Kong Stock Exchange. Their target clients include healthcare providers and patients seeking effective treatments for metabolic and immune diseases.Explore more
Ascletis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascletis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ascletis Pharma has new funding data
Earning: See what the market has to say on Ascletis Pharma recently announced quarterly report
Ascletis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Ascletis Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ascletis Pharma
Click to see if Ascletis Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Ascletis Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ascletis Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ascletis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ascletis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ascletis Pharma.
Ascletis Pharma financials insights
Gather financial insights about Ascletis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$100M
2015
Private Equity
$35M
Unspecified
$20M
2017
Series B
$100M
Ascletis Pharma Tech Stack
A closer look at the technologies used by Ascletis Pharma
See more technologies
Most Recent Scoops
Executive Move
Board of Directors
Executive Move
Board of Directors
Promotion
Executive Move
John Gargiulo has been promoted to the role of Chief Business Officer.
New Hire
Executive Move
New Hire
Executive Move
Ascletis Pharma News & Media
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its...Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 5, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a...Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG, April 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The...Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 26,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascletis Pharma
Sign Up For FreeTo access detailed company insights
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including... Read More
